American Thoracic Society - Sanofi Investor Call
Baseline Demographics and Disease Characteristics
Placebo
Dupilumab
Characteristic
(N = 471)
(N = 468)
All
(N = 939)
Type 2 inflammation biomarkers
Blood eosinophil count at randomization -
408 (331)
394 (261)
401 (298)
cells/μL, mean (SD)
Post-BD FeNo level, ppb, mean (SD)
23.5 (22.0)
25.2 (22.8)
24.3 (22.4)
FENO level ≥20 ppb, no. (%)
188 (42.5)
195 (45.0)
383 (43.8)
FENO level <20 ppb, no. (%)
254 (57.5)
238 (55.0)
492 (56.2)
Moderate-severe COPD exacerbations in 1-year
2.3 (1.0)
2.2 (1.1)
2.3 (1.0)
prior, mean (SD)
Lung function
Post-BD FEV₁ (L), mean (SD)
1.41 (0.47)
1.39 (0.47)
1.40 (0.47)
Post-BD FEV1% predicted mean (SD)
50.6 (13.0)
50.6 (13.3)
50.6 (13.1)
Post-BD FEV1/FVC, mean (SD)
0.5 (0.1)
0.5 (0.1)
0.5 (0.1)
SGRQ total score, mean (SD)
48.4 (17.8)
48.4 (17.0)
E-RS: COPD total score, mean (SD)
13.0 (6.9)
12.9 (7.2)
48.4 (17.4)
12.9 (7.1)
ATS 2023
24
24View entire presentation